利美替尼对比吉非替尼一线治疗EGFR敏感突变晚期NSCLC的3期试验
这项在中国56家医院开展的多中心、随机、双盲、双模拟3期试验,纳入337例EGFR敏感突变(19外显子缺失或21外显子L858R)的局部晚期或转移性NSCLC患者,按1:1随机接受利美替尼80 mg每日两次或吉非替尼250 mg每日一次治疗。两组3级及以上治疗相关不良事件发生率均为25%,利美替尼组治疗相关严重不良事件9例(5%),吉非替尼组17例(10%)。
要点
- 两组3级及以上治疗相关不良事件发生率均为25%,安全性总体可管理。
- 利美替尼组治疗相关严重不良事件发生率5%,低于吉非替尼组的10%。
核心结论
- 利美替尼对比吉非替尼一线治疗EGFR敏感突变局部晚期或转移性NSCLC显示出更优的疗效,且安全性可管理,应考虑作为该人群的又一一线治疗选择。
研究设计与样本
- 多中心、随机、双盲、双模拟3期试验,在中国56家医院开展,共纳入337例患者,利美替尼组168例,吉非替尼组169例。
- eligible患者为年龄≥18岁、经中心实验室Cobas EGFR突变检测确认肿瘤组织存在EGFR敏感突变(19外显子缺失或21外显子L858R)的局部晚期或转移性NSCLC患者。
- 患者按1:1随机接受口服利美替尼80 mg每日两次联合吉非替尼匹配安慰剂250 mg每日一次,或口服吉非替尼250 mg每日一次联合利美替尼匹配安慰剂80 mg每日两次,21天为一周期。
- 随机分层因素为EGFR突变类型(19外显子缺失或21外显子L858R)和中枢神经系统转移(有或无),采用区组随机(区组大小4)通过交互式网络应答系统分配。
- 主要终点为独立中心评审(ICR)评估的无进展生存期;所有接受至少一剂研究治疗的患者纳入全分析集进行疗效分析,接受至少一剂研究治疗且完成至少一次安全性评估的患者纳入安全性集。
主要发现
- 利美替尼组168例中42例(25%)发生3级及以上治疗相关不良事件,吉非替尼组169例中42例(25%)发生。
- 利美替尼组治疗相关严重不良事件9例(5%),吉非替尼组17例(10%)。
- 利美替尼组6例(4%)患者因不良事件死亡,研究者认为均可能与研究药物无关;吉非替尼组7例(4%)患者因不良事件死亡,其中3例(2%)被研究者判定为可能与研究药物相关。
- 吉非替尼组记录3例治疗相关死亡(1例与肺炎相关,2例死因未知)。
关键数值与推荐
- EGFR敏感突变定义为19外显子缺失或21外显子L858R突变,经中心实验室Cobas EGFR突变检测在肿瘤组织样本中确认。
- 3级及以上治疗相关不良事件发生率两组均为25%(利美替尼组42/168,吉非替尼组42/169)。
- 治疗相关严重不良事件发生率利美替尼组5%(9/168),吉非替尼组10%(17/169)。
临床怎么用
- 对于EGFR敏感突变(19外显子缺失或21外显子L858R)的局部晚期或转移性NSCLC患者,利美替尼可作为一线治疗选择之一,其无进展生存期显著优于吉非替尼。
- 用药方案为利美替尼80 mg口服每日两次,21天为一周期,治疗持续至疾病进展或符合其他停药标准。
- 治疗期间需监测不良事件,利美替尼组3级及以上治疗相关不良事件发生率为25%,严重不良事件发生率为5%。
局限性
- 研究仅在中国56家医院开展,入组患者均为中国人群,结果外推至其他种族或地区需谨慎。
- 随访仍在进行中,总生存期等长期结局尚未报告。
- 利美替尼组有6例(4%)患者因不良事件死亡,虽研究者认为均可能与研究药物无关,但仍需关注安全性信号的长期评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limertinib is a new third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This study aimed to prospectively assess the efficacy and safety of limertinib versus gefitinib as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR-sensitising mutation. METHODS: This multicentre, randomised, double-blind, double-dummy, phase 3 trial was done at 56 hospitals in China. Eligible patients were aged ≥18 years with locally advanced or metastatic NSCLC with EGFR-sensitising mutation (exon 19 deletion or exon 21 L858R mutation) detected in tumour tissue samples using the Cobas EGFR Mutation Test at a central laboratory. Patients were randomly assigned (1:1) to receive oral limertinib 80 mg twice a day and gefitinib-matching placebo 250 mg once a day or oral gefitinib 250 mg once a day plus limertinib-matching placebo 80 mg twice a day in 21-day cycles, until disease progression or other discontinuation criteria was met. Random assignment was stratified according to EGFR mutation type (exon 19 deletion or exon 21 L858R mutation) and CNS metastasis (yes or no) using permuted blocks (block size four) through an interactive web-based response system. The primary endpoint was independent central review (ICR)-assessed progression-free survival. All enrolled patients who received at least one dose of study treatment were included in the full analysis set for efficacy analysis. All enrolled patients who received at least one dose of study treatment and one safety assessment were included in the safety set. This study is registered with ClinicalTrials.gov, NCT04143607, and follow-up is ongoing. FINDINGS: Between June 30, 2021, and Sept 22, 2022, 337 patients were enrolled and 168 were randomly assigned to the limertinib group and 169 to the gefitinib group. Patients' median age was 63 years (34-82). 214 (64%) of 337 patients were female and 123 (36%) were male. The median masked ICR-assessed progression-free survival was 20·7 months (95% CI 15·2-22·1) in the limertinib group and 9·7 months (95% CI 8·3-11·1) in the gefitinib group (hazard ratio [HR] 0·44 [95% CI 0·34-0·58]; p<0·0001). Treatment-related adverse events of grade 3 or worse occurred in 42 (25%) of 168 patients in the limertinib group and 42 (25%) of 169 patients in the gefitinib group. Treatment-related serious adverse events occurred in nine (5%) patients and 17 (10%) patients in each group, respectively. Six (4%) patients in the limertinib group died due to adverse events, all of which were considered possibly unrelated to the study drug by investigators. In the gefitinib group, seven (4%) patients died due to adverse events, with three (2%) of those deaths judged as possibly related to the study drug by investigators. Three treatment-related deaths in the gefitinib group were recorded (one case related to pneumonia and two with cause of death unknown). INTERPRETATION: Limertinib showed superior efficacy compared with gefitinib and a manageable safety profile for locally advanced or metastatic NSCLC patients with EGFR-sensitising mutation and should be considered as another first-line treatment option for this patient population. FUNDING: Jiangsu Aosaikang Pharmaceutical. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Shi Y, Wu L, Ji Y, et al. Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med. 2025. PMID: 40550238. doi:10.1016/S2213-2600(25)00121-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。